|
Apr 16
|
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
|
|
Apr 16
|
Intra-Cellular Launches 23% To Record High, Breaking Out After Depression Drug Scores Big
|
|
Apr 16
|
Intra-Cellular builds case for depression drug with late-stage trial win
|
|
Apr 16
|
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
|
|
Mar 24
|
Intra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467%
|
|
Mar 19
|
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
|
|
Mar 12
|
Intra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 Shares
|
|
Mar 6
|
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
|
|
Feb 15
|
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 15
|
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 13
|
Biotech Leader Intra-Cellular Therapies Nears Buy Point Ahead Of Earnings Report
|
|
Feb 12
|
Dow Jones Futures: Market Risks Rising With 5 Stocks In Buy Zones
|
|
Feb 12
|
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Path To Profitability
|
|
Jan 13
|
Intra-Cellular Therapies Inc EVP and General Counsel Michael Halstead Sells 50,000 Shares
|
|
Jan 12
|
16 Best Mid-Cap Growth Stocks To Buy Now
|
|
Jan 5
|
Intra-Cellular Therapies Inc EVP Suresh Durgam Sells 62,282 Shares
|
|
Jan 1
|
Intra-Cellular Therapies (ITCI) Now Trades Above Golden Cross: Time to Buy?
|
|
Dec 20
|
11 Most Promising Psychedelic Stocks According to Hedge Funds
|
|
Dec 19
|
Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?
|
|
Dec 18
|
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
|